Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy
|Filename||211. Casale et al., Similar eff. omalizumab ciu csu, JACI Pract. 2015.pdf|
|Date added||July 29, 2020|
|Tags||Antihistamine, Chronic idiopathic, Chronic spontaneous, hive, itch, omalizumab, Pruritus, urticaria, wheal|
|Authors||Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.|
|Citation||Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750.|
|Corresponding authors||Rosén, K.|
|Edition; Page||3; 743-750|
|Publisher||J. Allergy Clin. Immunol. Pract.|
Background: Data from the 3 omalizumab pivotal trials inpatients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) represent the largest database of patients reported to date with refractory disease (omalizumab, n[733;placebo, n[242).
Objective: The objective of this study was to compare results from ASTERIA I and II, which included only approved doses ofH1-antihistamine as background therapy based on regulatory authority requirements, to those from GLACIAL, which permitted higher doses of H1-antihistamines as well as other types of background therapy, in aposthocanalysis.
Methods: Efficacy data from the placebo, omalizumab 150-mg, and omalizumab 300-mg treatment arms of ASTERIA I andII were pooled and analyzed (n[162 and n[160, respectively). The 300-mg treatment arm analyses were compared with the analysis of data from GLACIAL (n[252) using analysis of covariance models. The key efficacy endpoint was change from baseline to week 12 in mean weekly itch severity score (ISS);
(Last update: 08.2021)
|Number of publications (original work and reviews) in peer-reviewed journals:||636|
|Number of original publications in peer-reviewed journals:||462|
|Number of reviews in peer-reviewed journals:||174|
|Cumulative IF of publications (original work & reviews) in peer-reviewed journals:||3834,12|
|Cumulative IF for original publications in peer-reviewed journals:||3043,14|
|Cumulative IF for reviews in peer-reviewed journals:||790,98|
|Citations, Hirsch index: (view on Web of Science)||26429|